News

Turbocharged CAR-T cells melt tumours in mice — using a trick from cancer cells

Immune cells armed with a mutation first identified in cancer cells gain potency but don’t turn cancerous themselves. “Natural T-cell function isn’t good enough. We need to explore the extremes of T-cell function,” says Kole Roybal, an immunologist at the University of California, San Francisco,...

Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution

Aclarion, a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (cLBP), announced today the product release of Nociscan 2.6 which includes support for additional leading...

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262

Sana Biotechnology, a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to initiate a study of SC262 in patients with relapsed or refractory...

EndeavorRx, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17

Akili, a leading digital medicine company, today announced that it has received authorization from the U.S. Food and Drug Administration (FDA) to expand the label for EndeavorRx® from 8 to 12-year-old patients with primarily inattentive or combined-type ADHD who have a demonstrated attention issue...

BeeKeeperAI Expands Privacy-Enhancing Innovation with New Patent, New Product, and New Advantages to Accelerate Responsible AI in Healthcare

BeeKeeperAI, a pioneer in privacy-enhancing, multi-party collaboration software, today announced the next step in its innovation strategy for EscrowAI™ with automated, privacy-enhancing workflows to advance the responsible development and deployment of AI for healthcare. Dr. Michael Blum is the...

Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders

Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator. This technology was licensed from Dr. Tejal Desai’s lab where...

Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform

Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS-T cell therapies, today announced that it has closed a $51 million Series A financing. The oversubscribed round was led by EQT Life Sciences, F-Prime Capital, and Eight Roads Ventures Japan, with...

Chroma Medicine Highlights Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting

Chroma Medicine, a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the potential of its multiplex epigenetic editing platform to enhance functional allogeneic chimeric antigen receptor (CAR) T cells at the American Society of...

Trial Library, oncology clinical trial technology company, announces release of provider decision support platform to advance access to trials in community oncology settings

Trial Library, Inc., an oncology clinical trials company, today announced it has launched a provider decision support platform to advance access to oncology clinical trials in community settings. The platform will support all oncology treatment clinical trials and has provided an initial release to...

Exai Bio’s RNA- and AI-based Liquid Biopsy Platform Detects Early Stage Breast Cancer with High Accuracy

Exai Bio today announced new data demonstrating that its novel RNA-based and AI-driven liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes, including ductal carcinoma in situ (DCIS), using a standard blood sample. In a new early detection study...